YMAB | Y-mAbs Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)

*Sign In to persist settings

Financial Year End	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	84.82M	65.27M	34.90M	20.75M	N/A	N/A	N/A	N/A
Cost of Revenue	11.42M	7.57M	2.51M	2.20M	166.00K	29.00K	N/A	N/A
Gross Profit	73.40M	57.70M	32.38M	18.55M	-166.00K	-29.00K	N/A	N/A
Operating Expenses	99.08M	152.51M	147.82M	138.48M	83.00M	43.23M	19.24M	17.04M
Selling, General & Admin	44.86M	60.94M	54.57M	44.78M	19.51M	8.96M	4.94M	3.18M
Research & Development	54.22M	91.57M	93.25M	93.70M	63.49M	34.27M	14.31M	13.86M
Other Operating Expenses	N/A	N/A	62.01M	-2.20M	N/A	-44.00K	83.00K	-18.00K
Operating Income	-25.67M	-94.81M	-115.43M	-119.94M	-83.00M	-43.23M	-19.24M	-17.04M
Other Expenses / Income	4.81M	-757.00K	60.16M	598.00K	1.98M	-44.00K	83.00K	-18.00K
Before Tax Income	-20.87M	-95.57M	-55.27M	-119.34M	-81.03M	-43.27M	-19.16M	-17.06M
Income Tax Expenses	561.00K	757.00K	1.07M	-994.00K	-2.14M	-44.00K	-19.24M	-17.04M
Net Income	-21.43M	-96.33M	-56.34M	-118.34M	-78.89M	-43.27M	-19.16M	-17.06M
Interest Expenses	N/A	757.00K	1.85M	598.00K	1.98M	N/A	N/A	N/A
Basic Shares Outstanding	43.65M	43.70M	43.18M	40.12M	35.18M	28.77M	33.29M	33.29M
Diluted Shares Outstanding	43.65M	43.70M	43.18M	40.12M	35.18M	28.77M	33.29M	33.29M
EBITDA	-25.67M	-94.73M	-54.49M	-119.54M	-82.84M	-43.20M	83.00K	-18.00K
EBITDA Margin	-30.27%	-145.14%	-156.15%	-576.09%	0.00%	0.00%	0.00%	0.00%
EBIT	-20.87M	-94.81M	-53.42M	-118.74M	-79.05M	-43.32M	-38.41M	-34.10M
EBIT Margin	-24.60%	-145.27%	-153.09%	-572.24%	0.00%	0.00%	0.00%	0.00%
Financial Year End	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31